Breast Cancer Clinical Trial

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients

Summary

The objective of the study is to serve as a correlative study for patients enrolled on the RadCOMP trial (NCT02603341), a randomized phase III study of stage II and III breast cancer patients treated with either conventional photon radiation or proton beam radiation

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Eligible for and scheduled to receive radiation therapy on Radiation Therapy Oncology Group (RTOG) Trial 3510 (Pragmatic Phase III Randomized Trial of Proton vs Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial). (NCT02603341)
Ability to understand and the willingness to sign a study-specific written informed consent document

Exclusion Criteria:

There are no exclusion criteria.

Study is for people with:

Breast Cancer

Estimated Enrollment:

100

Study ID:

NCT03270072

Recruitment Status:

Recruiting

Sponsor:

Massachusetts General Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Rachel Jimenez, MD
Contact
617-726-7559
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

100

Study ID:

NCT03270072

Recruitment Status:

Recruiting

Sponsor:


Massachusetts General Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider